1+ week, 1+ day ago   (334+ words) Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone. Personalized cancer treatment aims to match patients with therapies based on specific features of their cancer, but tumors can…...

3+ mon, 3+ week ago   (569+ words) ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances. Dr. Josh K. Sabari, a thoracic medical oncologist at NYU Langone’s Perlmutter Cancer Center and editor-in-chief of CURE, discussed the most anticipated lung cancer…...

4+ mon, 2+ week ago   (371+ words) Immunotherapy boosts the immune system to fight cancer but may cause skin side effects; early reporting helps manage symptoms and keep treatment on track. Immunotherapy has transformed cancer treatment by helping the body’s immune system recognize and attack cancer cells…...

5+ mon, 4+ day ago   (10+ words) Expert Dr. Sheri Prentiss Discusses Early Lymphedema Risk Assessment Cure Today...

5+ mon, 3+ week ago   (286+ words) Metastatic breast cancer survivor Casey Liening shares her adoption story in a candid interview. In a candid interview with CURE conducted during the 49th annual Miami Breast Cancer Conference, Liening explored the complexities of advocacy, the stigma of stage 4 and the…...

5+ mon, 3+ week ago   (428+ words) A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization. Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in…...

6+ mon, 8+ hour ago   (53+ words) Historic Breakthrough in Platinum-Resistant Ovarian Cancer Treatment(2) Cure Today INT230-6 Combination Increases Response Rates in Triple-Negative Breast Cancer Expert Explains Keytruda Combo Survival Gains in Resistant Ovarian Cancer New Test Predicts Breast Cancer Recurrence and Radiation Therapy Benefit FDA Grants Priority…...

6+ mon, 1+ day ago   (104+ words) Dr. Chandler Park, of Norton Healthcare, and Dr. Joshua Sabari, of NYU Langone Health Perlmutter Cancer Center, discussed key updates from the 2026 ASCO Genitourinary Cancers Symposium. In this clip, they highlight how radioligand therapy works. This “smart bomb” approach is…...

6+ mon, 2+ week ago   (296+ words) "QoL end points are essential for assessing patient-centered outcomes in GU cancers, yet their inclusion and reporting in clinical trials remain inconsistent,” lead author, Dr. Shreyas Kalantri, wrote in a poster presentation of the data. “Despite growing emphasis on PROS,…...

6+ mon, 2+ week ago   (573+ words) CUREtoday.com Kidney cancer is not exclusively a disease of older patients. For many young adults, the diagnosis comes as a shock, often appearing without warning in those who otherwise feel healthy. In light of the death of Brad Arnold,…...